

Message

From: Striegel, Wiebke [Striegel.Wiebke@epa.gov]
Sent: 10/5/2021 8:11:43 PM
To: Ortiz, Nina [Ortiz.Nina@epa.gov]; Kirk, Cassandra [kirk.cassandra@epa.gov]
CC: Mendelsohn, Mike [Mendelsohn.Mike@epa.gov]
Subject: Meeting on intradermal hazard assessment
Attachments: Intradermal 1-pager 091621.docx

Hello,

I just forwarded you a calendar invite for Friday, October 15th. As Mike mentioned in the last meeting, we have just started a discussion within OPP on how to potentially address the allergenicity assessment for proteins with a potential for intradermal exposure (so far that would only be female mosquitoes, but it could be other biting insects in the future). We had briefly talked to Anna Lowit last Friday and she connected us with NICEATM at NIH. This is the group that developed and validated the new *in vitro* guidance studies that OPP is using for various hazard assessments instead of animal models.

The meeting on that Friday is the first one with NICEATM. The goal will be to first lay out the issue and gauge the capabilities within their group to address the allergenicity angle. We may or may not end up working with them on this issue, but of course the idea of having a potential *in vitro* assay that can be used for this purpose is exciting.

For your background I am also attaching a brief one pager to this email that we shared with Anna last Friday.

Wiebke

Wiebke Tapken Striegel, Ph.D.
Senior Scientist
U.S. Environmental Protection Agency
Office of Pesticide Programs
Biopesticides and Pollution Prevention Division
Emerging Technologies Branch
Office Phone: +1 703 347 0556